Hospitals warn CGHS reimbursement cap may hurt cancer treatment

Many hospitals procure patented immunotherapy drugs through bulk contracts with multinational pharmaceutical companies; contracts that explicitly prohibit disclosure of negotiated prices to third parties. Submitting purchase invoices to the CGHS, hospitals warn, could expose them to breach of contract claims, and the drugmakers can initiate legal proceedings or stop the supply of these medicines.